- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07863024
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
A Phase 1/2 Study of REGN13089-M404-M2980, a MET-targeting Antibody-Drug Conjugate in Adult Participants With Previously Treated Advanced Solid Tumors
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).
The study is focused on advanced cancers that have more of a protein called mesenchymal epithelial transition factor (MET) on the surface of their cells than usual. The study drug works by binding to MET on tumor cells and delivering chemotherapy directly into those cells. This may stop growth of the cancer cells and kill only the cancer cells and not the other normal tissues in your body. However, some of the chemotherapy may still affect the normal cells and side effects can still occur.
The study is looking at:
- What side effects the study drug might cause
- How well the study drug works
- How much of the study drug is in the blood at different times
- If the body reacts to the study drug, in a way that may cause the study drug to not work as well
- What is the best dose of the study drug for treating previously treated, advanced solid tumors
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Clinical Trials Administrator
- Numéro de téléphone: 844-734-6643
- E-mail: clinicaltrials@regeneron.com
Lieux d'étude
-
-
North Carolina
-
Huntersville, North Carolina, États-Unis, 28078
- Recrutement
- Carolina BioOncology Institute
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria:
- Histologically confirmed cancer (non-small cell lung cancer (epidermal growth factor receptor mutant type or epidermal growth factor receptor mutant type), colorectal cancer, gastric/gastroesophageal junction cancer, uveal melanoma, papillary renal cell carcinoma, or clear cell renal cell carcinoma) that is at an advanced stage as described in the protocol
- Participants must not be candidates for curative surgery or radiation
- Participants are required to have exhausted all therapeutic options that are expected to provide meaningful clinical benefit, either through disease relapse, treatment refractory disease, or intolerance of the therapy as described in the protocol
- Willing to provide tumor tissue; archival or fresh tumor tissue will be accepted as described in the protocol
- At least 1 lesion that is measurable by RECIST 1.1. Tumor lesions in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions after radiation
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ and bone marrow function as described in the protocol
Key Exclusion Criteria:
- Has received treatment with an approved systemic therapy or has participated in any study of an investigational agent or investigational device as described in the protocol
- Has received radiation therapy within the 28 days prior to first administration of study intervention. Palliative stereotactic radiation therapy without a thoracic or abdominal field is allowed with a washout period of 14 days from first administration of study intervention.
- Has undergone major surgery within the 14 days prior to first administration of study intervention
- Has not yet recovered (ie, grade ≤1 or baseline) from any acute toxicities resulting from prior therapy as described in the protocol
- Has a history of interstitial lung disease (eg, idiopathic pulmonary fibrosis, etc) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management or has imaging consistent with these diseases during the screening period. A history of radiation pneumonitis is permitted as long as pneumonitis resolved ≥6 months prior to enrollment.
- Has received prior treatment with an antibody-drug conjugate (ADC) that includes a topoisomerase payload
- Known active or untreated brain metastases or spinal cord compression. Participants are eligible if central nervous system (CNS) metastases are adequately treated, and participants have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment.
Note: Other protocol defined inclusion/ exclusion criteria apply
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Partie 1 : Augmentation de la dose
|
Administered per the protocol |
|
Expérimental: Partie 2 : Expansion de la dose
|
Administered per the protocol |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Occurrence of dose-limiting toxicities (DLTs)
Délai: Up to 21 days
|
Part 1 (Dose Escalation) |
Up to 21 days
|
|
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Délai: Up to approximately 5 years
|
Part 1 (Dose Escalation) |
Up to approximately 5 years
|
|
Occurrence of Serious Adverse Events (SAEs)
Délai: Up to approximately 5 years
|
Part 1 (Dose Escalation) |
Up to approximately 5 years
|
|
Occurrence of adverse event of special interests (AESIs)
Délai: Up to approximately 5 years
|
Part 1 (Dose Escalation) |
Up to approximately 5 years
|
|
Objective response (OR) (investigator assessed) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Délai: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Objective response (investigator assessed) per RECIST 1.1
Délai: Up to approximately 5 years
|
Part 1 (Dose Escalation) |
Up to approximately 5 years
|
|
Concentrations of ADC
Délai: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Concentrations of total antibody
Délai: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Concentrations of payload (ProDXd and DXd)
Délai: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Occurrence of Anti-Drug Antibodies (ADA) against REGN13089-M404-M2980
Délai: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Magnitude of ADA against REGN13089-M404-M2980
Délai: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Duration of response per RECIST 1.1
Délai: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Time to response per RECIST 1.1
Délai: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Progression-free survival per RECIST 1.1
Délai: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Overall survival
Délai: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Occurrence of TEAEs considered clinically significant
Délai: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Laboratory abnormalities considered clinically significant
Délai: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Clinical Trial Management, Regeneron Pharmaceuticals
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
- NSCLC
- RENCONTRÉ
- Cancer colorectal
- Cancer de l'estomac
- Cancer du poumon non à petites cellules
- Cancer avancé
- Métastatique
- Non résécable
- Cancer de la jonction gastro-oesophagienne
- Tumeur solide métastatique
- ADC
- Premier humain
- Mélanome uvéal
- Conjugué anticorps-médicament
- Carcinome à cellules claires du rein
- FIH
- Malignité solide avancée
- Carcinome papillaire à cellules rénales
- METxMET antibody-drug conjugate
- Solid neoplasm
- Unresectable solid tumor
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Processus pathologiques
- Tumeurs urogénitales
- Tumeurs par site
- Tumeurs
- Maladies urogénitales masculines
- Maladies rénales
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladies intestinales
- Maladies des voies respiratoires
- Tumeurs par type histologique
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies du système digestif
- Maladies gastro-intestinales
- Maladies de l'estomac
- Tumeurs intestinales
- Maladies rectales
- Maladies pulmonaires
- Maladies oculaires
- Tumeurs, glandulaires et épithéliales
- Adénocarcinome
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Maladies du côlon
- Processus néoplasiques
- Tumeurs pulmonaires
- Tumeurs urologiques
- Carcinome
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Tumeurs rénales
- Carcinome bronchique
- Tumeurs bronchiques
- Tumeurs neuroendocrines
- Nevi et mélanomes
- Tumeurs oculaires
- Maladies de l'uvée
- Mélanome
- Conditions pathologiques, signes et symptômes
- Tumeurs de l'uvée
- Tumeurs de l'estomac
- Tumeurs colorectales
- Métastase néoplasmique
- Carcinome à cellules rénales
- Carcinome pulmonaire non à petites cellules
- Mélanome uvéal
Autres numéros d'identification d'étude
- R13089-ONC-25128
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Délai de partage IPD
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Critères d'accès au partage IPD
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- ANALYTIC_CODE
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .